Loading…
Sutro Biopharma, Inc. is projected to rise to $36.41 by 2027, a +23% move from its current price of $29.69. STRO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.12 | $29.71 | $31.39 | +0.06% |
| May 30 | $27.50 | $29.72 | $32.13 | +0.11% |
| May 31 | $27.04 | $29.74 | $32.71 | +0.17% |
| Jun 1 | $26.66 | $29.76 | $33.22 | +0.23% |
| Jun 2 | $26.33 | $29.77 | $33.67 | +0.28% |
| Jun 3 | $26.04 | $29.79 | $34.09 | +0.34% |
| Jun 4 | $25.77 | $29.81 | $34.48 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.77 | $29.81 | $34.48 | +0.40% |
| Week 2 | $24.36 | $29.93 | $36.77 | +0.80% |
| Week 3 | $23.35 | $30.05 | $38.66 | +1.20% |
| Week 4 | $22.55 | $30.17 | $40.36 | +1.60% |
| Week 5 | $21.87 | $30.29 | $41.94 | +2.01% |
| Week 6 | $21.29 | $30.41 | $43.43 | +2.42% |
| Week 7 | $20.77 | $30.53 | $44.87 | +2.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer.
The company also develops VAX-24 and Vax-31 pneumococcal vaccine candidates that are in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc.
to develop immunostimulatory ADC. The company was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma, Inc. (STRO) is an oncology-focused biopharma company with a portfolio that includes ADCs and vaccine candidates, along with strategic collaborations. It trades with a current price of $29.69 and a market cap of $491.98M, ranking 3021 by market position.
The stock’s outlook is driven by a multi-year forecast that shows a bullish trajectory, with increasing average prices through 2030 and beyond, highlighted by a long-term path to higher levels.
A major floor 53.5% below — a decisive break under it would weaken the trend.
The nearest floor, 13.9% below — buyers have tended to step in here.
The nearest ceiling, 37.8% above — a clean break opens room to run.
A major ceiling 59.6% above — clearing it would confirm fresh momentum.
Key STRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.88 | Buy | $29.53 | Buy |
| MA 10 | $32.75 | Sell | $31.62 | Sell |
| MA 20 | $35.44 | Sell | $33.04 | Sell |
| MA 50 | $30.53 | Sell | $30.57 | Sell |
| MA 100 | $23.76 | Buy | $25.55 | Buy |
| MA 200 | $16.52 | Buy | $20.72 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.62 | Neutral |
| Stoch RSI (14) | 26.71 | Neutral |
| CCI (20) | -101.97 | Sell |
| Williams %R (14) | -73.14 | Info |
| MACD (12,26,9) | -1.61 | Sell |
| ROC (12) | -26.22 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 26.86 | Neutral |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | -4.89 | Sell |
| Ultimate (7,14,28) | 30.47 | Neutral |
| Momentum (10) | -11.22 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 25.84 | Buy |
| ADX (14) | 32.05 | Sell |
| ATR (14) | 1.65 | Info |
The 30-day technical picture is overall bullish in sentiment, with momentum that supports further upside. The RSI(14) stands at 40, suggesting room for upside before reaching overbought territory, while the SMA50 is listed at $30.53 and the SMA200 at $16.52, placing the current price near the short-term moving average.
The 30-day price range runs from a low of $20.66 to a high of $42.67, indicating substantial recent volatility but providing clear support and resistance levels. A nearby support level is pegged at $25.57 and a resistance level at $40.91, outlining a trading band within which near-term moves may unfold.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.63 | $29.69 | $51.16 | 0% | Neutral | |
| $26.20 | $36.41 | $54.74 | +23% | Bullish | |
| $31.43 | $46.35 | $74.10 | +56% | Bullish | |
| $30.99 | $48.10 | $80.62 | +62% | Bullish | |
| $32.40 | $52.70 | $91.87 | +78% | Bullish | |
| $48.86 | $83.03 | $149.76 | +180% | Bullish | |
| $54.71 | $96.96 | $180.24 | +227% | Bullish | |
| $59.09 | $109.03 | $208.25 | +267% | Bullish | |
| $59.92 | $115.01 | $225.17 | +287% | Bullish | |
| $50.97 | $101.69 | $203.67 | +243% | Bullish | |
| $91.80 | $204.01 | $448.73 | +587% | Bullish | |
| $253.40 | $563.11 | $1,295.16 | +18.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $10.63 | $29.69 | $35.07 | +0.00% |
| June 2026 | $24.15 | $28.96 | $35.99 | -2.44% |
| July 2026 | $25.64 | $31.27 | $39.86 | +7.96% |
| August 2026 | $27.14 | $33.55 | $43.59 | +7.28% |
| September 2026 | $26.82 | $33.52 | $44.23 | -0.09% |
| October 2026 | $27.36 | $34.55 | $46.24 | +3.08% |
| November 2026 | $29.13 | $37.12 | $50.28 | +7.43% |
| December 2026 | $29.05 | $37.34 | $51.16 | +0.59% |
Click any year to see its month-by-month STRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect STRO to range from $10.63 to $51.16 through 2026. The $29.69 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The STRO price prediction for 2027 points to an average of $36.41 (low $26.20, high $54.74) — a potential gain of +23% on today's $29.69. Momentum favours further upside here.
In 2028, STRO is projected to trade between $31.43 and $74.10, averaging $46.35 — a potential gain of +56% from today's $29.69. That is up +27% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Sutro Biopharma, Inc.'s 2029 outlook centres on $48.10, within a $30.99 to $80.62 range. That is up +4% on the projected 2028 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2030, STRO could reach as high as $91.87, with a base case around $52.70 and support toward $32.40 — roughly +78% from $29.69. Buyers look set to stay in control over this stretch.
Expect STRO to range from $48.86 to $149.76 through 2031. The $83.03 average target implies a +180% move from current prices. That is up +58% on the projected 2030 average. Momentum favours further upside here.
The STRO price prediction for 2032 points to an average of $96.96 (low $54.71, high $180.24) — a potential gain of +227% on today's $29.69. Buyers look set to stay in control over this stretch.
In 2033, STRO is projected to trade between $59.09 and $208.25, averaging $109.03 — a potential gain of +267% from today's $29.69. That is up +12% on the projected 2032 average. Momentum favours further upside here.
Sutro Biopharma, Inc.'s 2034 outlook centres on $115.01, within a $59.92 to $225.17 range. That is up +5% on the projected 2033 average. That marks a +287% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, STRO could reach as high as $203.67, with a base case around $101.69 and support toward $50.97 — roughly +243% from $29.69. Momentum favours further upside here.
Expect STRO to range from $91.80 to $448.73 through 2040. The $204.01 average target implies a +587% move from current prices. That is up +101% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The STRO price prediction for 2050 points to an average of $563.11 (low $253.40, high $1,295.16) — a potential gain of +18.0x on today's $29.69. Momentum favours further upside here.
Investing $1,000 in STRO today (≈ 33.681374 STRO) could be worth
$18,966.35
+$17,966.35 (+1797%) by 2050 · US Dollar
Based on the average projected STRO price of $563.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STROwould be worth at today's price.
$1,000 invested in STRO on May 27, 2025 (≈ 106.382983 STRO) would be worth
$3,158.51
+$2,158.51 (+215.9%) today · 3.16× · US Dollar
Based on a STRO entry price of $9.4 vs. today's $29.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.13 | $953.74 | -4.6% |
| 1 month ago | $33.59 | $883.89 | -11.6% |
| 3 months ago | $20.47 | $1,450.42 | +45.0% |
| 6 months ago | $9.2 | $3,227.17 | +222.7% |
| 1 year ago | $9.4 | $3,158.51 | +215.9% |
| All time (5.0y) ago | $180.8 | $164.21 | -83.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STRO forecast.
Our base-case forecast reaches $59.00 around 2031.
Implied market cap at $59.00: $977.66M
The multi-year forecast paints a strong bullish arc for Sutro Biopharma. By 2030 the average price is projected at $52.70 with a min of $32.40 and a max of $91.87, and an ROI of 77.5%. The sentiment for 2030 is bullish.
Earlier years show continued upside as well, with 2027 averaging $36.41 and 2028 averaging $46.35, both bearing bullish sentiment and positive ROIs (22.6% in 2027 and 56.1% in 2028).
Looking further out, 2040 carries an average forecast of $204.01 with a min of $91.80 and a max of $448.73, and a sizable ROI of 587.1%, with bullish sentiment continuing. By 2050, the average forecast reaches $563.11, with a min of $253.40 and a max of $1,295.16, and a projected ROI of 1796.6% while remaining bullish.
These figures illustrate a long-run upside scenario under the presented forecasts, though they are estimates and not guarantees. Real-world results depend on market conditions, clinical progress, regulatory outcomes, and other factors not controlled by the forecast.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $52.70, with a min of $32.40 and a max of $91.87; ROI is 77.5%, and the sentiment is BULLISH.
The forecast indicates a bullish path from 2027 onward, with average prices rising from $36.41 in 2027 to $204.01 by 2040 and $563.11 by 2050, and ROIs reaching 22.6% in 2027 and 1796.6% by 2050. However, these are estimates, not guarantees.
No. The 2030 max forecast is $91.87, which is below $100.
Current price is $29.69 with a 30-day range of $20.66 to $42.67. The support is $25.57 and the resistance is $40.91. RSI(14) is 40, SMA50 is $30.53, and SMA200 is $16.52, indicating a bullish longer-term tilt with near-term caution.
The current price is $29.69 and the market cap is $491.98M. The stock is ranked 3021 by market position.
Sutro Biopharma, Inc. Community Discussion
0Share your Sutro Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.